Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Identification of Somatic Genetic Variants in Superficial Vascular Malformations by Liquid Biopsy in a Cohort of 88 Patients from a French Hospital.
El Sissy FN et al.
Molecular Diagnosis & Therapy, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer-Current State and Molecular Pathology Perspective.
Liu L et al.
Cancers, 2024
PIK3CA Mutations and Co-Mutations in Operated Non-Small Cell Lung Carcinoma.
Cokpinar S et al.
Journal of Clinical Medicine, 2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Variation Analysis in Premenopausal and Postmenopausal Breast Cancer Cases.
Erdogdu IH et al.
Journal of Personalized Medicine, 2024
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S et al.
Scientific Reports, 2022
Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer.
Niu L et al.
Oncology Letters, 2021
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.
da Silva EM et al.
Npj Breast Cancer, 2021
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing.
Xu Z et al.
Oncotargets and Therapy, 2020
Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
Saba NF et al.
Plos One, 2020
Mutation profiling of cancer drivers in Brazilian colorectal cancer.
Dos Santos W et al.
Scientific Reports, 2019
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E et al.
Genes, 2019
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.
Lier A et al.
Jco Precision Oncology, 2018
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K et al.
Investigational New Drugs, 2017
Identification of frequent somatic mutations in inflammatory breast cancer.
Matsuda N et al.
Breast Cancer Research and Treatment, 2017
Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.
Li ZZ et al.
Medical Oncology (northwood, London, England), 2016
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M et al.
Oncotarget, 2016
Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.
Xiang L et al.
Oncotarget, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas.
Liu CX et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
Zhou JX et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2013
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN et al.
Plos One, 2013
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Liao X et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
Liu R et al.
The Journal of Clinical Endocrinology and Metabolism, 2011
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Simi L et al.
American Journal of Clinical Pathology, 2008
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Abubaker J et al.
Oncogene, 2008
Mutation of the PIK3CA gene in anaplastic thyroid cancer.
García-Rostán G et al.
Cancer Research, 2005